"Icon Cancer Foundation supports the development of new and improved medications for patients in our care via clinical trials. We continue to improve patient access to medication through the promotion of clinical trial, via community fundraising that help to provide patient programs and doctor or nurse initiated trials that support best patient care. Icon Cancer Foundation uses funds raised to support patients on clinical trials who may have otherwise not been able to participate. This includes transport and accommodation support along with access to personal cancer care coordinators and allied health services to ensure patients achieve the best possible outcome from their trial."

During the past decade, ICON Cancer Foundation conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ICON Cancer Foundation" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Pfizer" with 5 trials sponsored, "Akesobio Australia Pty Ltd" with 3 trials sponsored, "BeiGene" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ICON Cancer Foundation" #1 collaborator was "Astellas Pharma Inc" with 3 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 3 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "Chugai" with 1 trials as a collaborator and "Exelixis" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "ICON Cancer Foundation" are "Neoplasms Malignant" (2 trials), "Prostate Cancer" (2 trials), "Advanced Cancer" (1 trials), "Advanced Solid Tumors" (1 trials) and "B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion" (1 trials). Many other conditions were trialed in "ICON Cancer Foundation" in a lesser frequency.

Most popular intervention types in "ICON Cancer Foundation" are "Drug" (17 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Atezolizumab" (3 trials), "Carboplatin" (3 trials), "Enzalutamide" (3 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "ICON Cancer Foundation" are 14 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "ICON Cancer Foundation". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in ICON Cancer Foundation, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in ICON Cancer Foundation, 5 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".